KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Guardant Health (GH) Share-based Compensation (2017 - 2025)

Historic Share-based Compensation for Guardant Health (GH) over the last 9 years, with Q3 2025 value amounting to $42.8 million.

  • Guardant Health's Share-based Compensation fell 1398.66% to $42.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $159.4 million, marking a year-over-year increase of 2417.17%. This contributed to the annual value of $140.4 million for FY2024, which is 5470.75% up from last year.
  • Guardant Health's Share-based Compensation amounted to $42.8 million in Q3 2025, which was down 1398.66% from $42.5 million recorded in Q2 2025.
  • In the past 5 years, Guardant Health's Share-based Compensation ranged from a high of $55.1 million in Q1 2021 and a low of $20.6 million during Q3 2022
  • For the 5-year period, Guardant Health's Share-based Compensation averaged around $31.6 million, with its median value being $27.0 million (2024).
  • Per our database at Business Quant, Guardant Health's Share-based Compensation skyrocketed by 76887.03% in 2021 and then crashed by 5496.74% in 2022.
  • Guardant Health's Share-based Compensation (Quarter) stood at $26.9 million in 2021, then dropped by 11.74% to $23.7 million in 2022, then increased by 2.6% to $24.3 million in 2023, then surged by 49.53% to $36.4 million in 2024, then grew by 17.71% to $42.8 million in 2025.
  • Its last three reported values are $42.8 million in Q3 2025, $42.5 million for Q2 2025, and $37.8 million during Q1 2025.